Latest:
Supportive Care and Medication Access in GvHD
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
Latest:
Steroid-Refractory Acute GVHD
Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.
Corinne Summers, MD
Latest:
Dr. Summers on Role of CAR T Cells in Pediatric Cancer
Corinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.
Cornelis M. van Tilburg, MD, PhD
Latest:
Dr. van Tilburg on Larotrectinib in TRK+ Pediatric Cancers
Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children’s Cancer Center Heidelberg, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive cancers who have brain metastases or primary central nervous system tumors.
Costas Lallas, MD
Latest:
Dr. Lallas on Understanding Immunotherapy in GU Malignancies
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.
Courtney DiNardo, MD, MSCE
Latest:
Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS
Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup.
Craig Blinderman, MD
Latest:
Dr. Blinderman on Early Palliative Care for Patients With Metastatic Disease
Craig Blinderman, MD, Attending Physician in Medicine & Anesthesiology NewYork-Presbyterian Hospital/Columbia University Medical Center, Assistant Professor of Palliative Care (Medicine & Anesthesiology), Columbia University, discusses starting palliative care early in patients with metastatic disease.
Craig Moskowitz, MD
Latest:
Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCL
Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.
Craig Sauter, MD
Latest:
Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma
Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.